Quanterix Corporation announced that its Quanterix Accelerator Laboratory received a clinical laboratory permit from the New York State Department of Health in the clinical chemistry category, enabling full CLIA certification across all 50 states. This certification includes approval of their neurofilament light chain (NfL) laboratory-developed test, expanding the lab's capacity to deliver biopharma research, clinical testing, and custom assay development services. The lab supports both research and clinical diagnostics, including assays for neurodegenerative diseases such as Alzheimer's and multiple sclerosis.